Clincosm LogoSign in Get a demo

Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk

Sponsor
University of Alabama at Birmingham (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03040492
Collaborator
(none)
200
Enrollment
1
Location
133.2
Anticipated Duration (Months)
1.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to discover whether certain Vitamin D Receptor (VDR) gene polymorphisms are associated with an increased risk of cutaneous basal cell carcinoma (BCC) and/or cutaneous squamous cell carcinoma (SCC) in an Alabama population. Participant demographic information such as physical characteristics (e.g., ethnicity), family history, and cancer diagnosis will be collected in order to determine if there are relationships between the gene polymorphisms, cancer diagnosis, and these characteristics.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    200 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risks in Alabama Population
    Actual Study Start Date :
    Oct 31, 2012
    Anticipated Primary Completion Date :
    Sep 1, 2023
    Anticipated Study Completion Date :
    Dec 6, 2023

    Outcome Measures

    Primary Outcome Measures

    1. SIngle nucleotide polymorphisms (SNP) [2 years]

      Number of patients with the presence or absence of VDR SNP in their DNA isolated from their blood samples. PCR will be performed on the DNA samples for using specific primers for SNP, and the PCR products will be sequenced for detection of SNP.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Patients with non-melanoma skin cancer (cases)

    • Patients without non-melanoma skin cancer or history of non-melanoma skin cancer (controls)

    • Age 50 and older

    • Native English speakers

    • Patients at Kirklin Clinic

    Exclusion Criteria:

    • Age less than 50

    • Diagnosis of melanoma or other type of cancer

    • Non-English speakers

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Kirklin Clinic Birmingham Alabama United States 35294

    Sponsors and Collaborators

    • University of Alabama at Birmingham

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nabiha Yusuf, Principal Investigator, University of Alabama at Birmingham
    ClinicalTrials.gov Identifier:
    NCT03040492
    Other Study ID Numbers:
    • X120713008
    First Posted:
    Feb 2, 2017
    Last Update Posted:
    Aug 15, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Skin Neoplasms

    Study Results

    No Results Posted as of Aug 15, 2022